Zipalertinib trial meets primary endpoint in lung cancer study

Investing.com•Wed, Aug 12, 2026, 11:36 PM•2 min read

Developing story — details emerging. Check the source link for the latest updates.

Source: [Investing.com](https://www.investing.com/news/company-news/zipalertinib-trial-meets-primary-endpoint-in-lung-cancer-study-93CH-4856445)

📰 Read Full Story

This is an aggregated headline summary. For the complete report, visit the original publisher.

Continue Reading at Investing.com ↗

#finance #zipalertinib #trial #meets #primary #endpoint #lung #cancer #study

More Headlines

FinanceInvesting.com• 14m ago

Ford to shift Lincoln production to U.S. from China by 2030- Reuters

Developing story — details emerging. Check the source link for the latest updates.

FinanceSeeking Alpha• 17m ago

Allogene Therapeutics, Inc. (ALLO) Q2 2026 Earnings Call Transcript

Developing story — details emerging. Check the source link for the latest updates.

FinanceSeeking Alpha• 17m ago

Tantalus Systems Holding Inc. (GRID:CA) Discusses Q2 Performance Highlights and Opens Q&A Session Transcript

Developing story — details emerging. Check the source link for the latest updates.

FinanceSeeking Alpha• 17m ago

Fluence Energy: Record Orders Make Valuation More Interesting, But Execution Remains The Problem

Developing story — details emerging. Check the source link for the latest updates.

FinanceInvesting.com• 17m ago

Meta, 29 states head to court in biggest test yet of youth social media litigation

Developing story — details emerging. Check the source link for the latest updates.

FinanceBloomberg Markets• 18m ago

Singapore’s CapitaLand Sees Profit Recovery Due to Fee Increases

CapitaLand Investment Ltd. ’s profit rose in the first half, driven by higher contributions from private funds and various real estate investment trusts, and the property asset manager forecast earnings growth.